ZA200702537B - Pyridyl inhibitors of hedgehog signalling - Google Patents

Pyridyl inhibitors of hedgehog signalling

Info

Publication number
ZA200702537B
ZA200702537B ZA200702537A ZA200702537A ZA200702537B ZA 200702537 B ZA200702537 B ZA 200702537B ZA 200702537 A ZA200702537 A ZA 200702537A ZA 200702537 A ZA200702537 A ZA 200702537A ZA 200702537 B ZA200702537 B ZA 200702537B
Authority
ZA
South Africa
Prior art keywords
hedgehog signalling
pyridyl
inhibitors
pyridyl inhibitors
hedgehog
Prior art date
Application number
ZA200702537A
Other languages
English (en)
Inventor
Gunzner Janet
Stanley Mark
Castanedo Georgette
Wang Shumei
Savage Scott
Dina Michael
Sutherlin Daniel
Bao Liang
Lalonde Rebecca
Reynolds Mark
Malesky Kimberly
Original Assignee
Genentech Inc
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200702537(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Curis Inc filed Critical Genentech Inc
Publication of ZA200702537B publication Critical patent/ZA200702537B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/142—Esters of phosphorous acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200702537A 2004-09-02 2007-03-27 Pyridyl inhibitors of hedgehog signalling ZA200702537B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60736704P 2004-09-02 2004-09-02

Publications (1)

Publication Number Publication Date
ZA200702537B true ZA200702537B (en) 2008-08-27

Family

ID=35517336

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200702537A ZA200702537B (en) 2004-09-02 2007-03-27 Pyridyl inhibitors of hedgehog signalling

Country Status (25)

Country Link
US (8) US7888364B2 (xx)
EP (1) EP1789390B1 (xx)
JP (3) JP5143558B2 (xx)
KR (13) KR20210090744A (xx)
CN (2) CN102964294A (xx)
AT (1) ATE532768T1 (xx)
AU (3) AU2005282722C1 (xx)
BR (1) BRPI0514841B1 (xx)
CA (1) CA2579002C (xx)
CY (2) CY1112630T1 (xx)
DK (1) DK1789390T3 (xx)
EA (3) EA017262B1 (xx)
ES (1) ES2377430T3 (xx)
HU (1) HUS1300068I1 (xx)
IL (2) IL181673A (xx)
LU (1) LU92278I2 (xx)
MX (1) MX2007002584A (xx)
NO (1) NO339260B1 (xx)
NZ (1) NZ589385A (xx)
PL (1) PL1789390T3 (xx)
PT (1) PT1789390E (xx)
SI (1) SI1789390T1 (xx)
UA (1) UA96565C2 (xx)
WO (1) WO2006028958A2 (xx)
ZA (1) ZA200702537B (xx)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4368582B2 (ja) * 2001-01-13 2009-11-18 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 牛ウイルス性下痢ウイルス（ｂｖｄｖ）感染およびｃ型肝炎ウイルス（ｈｃｖ）感染を処置するのに有用な化合物、方法、および組成物
CN102964294A (zh) * 2004-09-02 2013-03-13 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
WO2006032273A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
MX2007016319A (es) * 2005-06-16 2008-03-10 Pfizer Derivados de n-(piridin-2-il)-sulfonamida.
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP5374363B2 (ja) * 2006-04-28 2013-12-25 モメンタ ファーマシューティカルズ インコーポレイテッド ペプチド混合物を評価する方法
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2527330A1 (en) 2007-03-14 2012-11-28 Exelixis, Inc. Inhibitors of the hedgehog pathway
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
PA8775801A1 (es) 2007-04-06 2009-05-15 Neurocrine Biosciences Inc Antagonista del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
CL2008000986A1 (es) 2007-04-06 2008-10-17 Neurocrine Biosciences Inc COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
CL2008001074A1 (es) 2007-04-18 2009-06-05 Merck & Co Inc Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
PL2187967T3 (pl) 2007-08-16 2013-09-30 Irm Llc Sposoby i kompozycje do leczenia raka
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
WO2009030952A2 (en) * 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
DE102007042754A1 (de) * 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
WO2009035568A1 (en) * 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
SI2195312T1 (sl) 2007-10-09 2013-01-31 Merck Patent Gmbh Derivati piridina, uporabni kot aktivatorji glukokinaze
GB0725214D0 (en) * 2007-12-24 2008-02-06 Karobio Ab Pharmaceutical compounds
CN101917853B (zh) 2007-12-27 2014-03-19 无限药品股份有限公司 立体选择性还原的方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
BRPI0911618A2 (pt) * 2008-04-29 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de ftalazina dissubstituída.
EP2303275A4 (en) * 2008-06-17 2012-05-09 Univ Duke STANDARD RECEPTOR MODULATORS
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
EP2617414A3 (en) * 2008-10-01 2013-11-06 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
PT2364185E (pt) 2008-11-03 2013-07-24 Lilly Co Eli Ftalazina dissubstituída antagonista da via hedgehog
CN102216285B (zh) 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
EP3725775A1 (en) 2009-02-17 2020-10-21 Syntrix Biosystems, Inc. Pyridine- and pyrimidinecarboxamides as cxcr2 modulators
EP2233566A1 (en) 2009-03-17 2010-09-29 Vrije Universiteit Brussel Generation of pancreatic progenitor cells
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
BRPI1011247A2 (pt) * 2009-06-09 2016-06-21 California Capital Equity Llc derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
WO2011014888A1 (en) * 2009-07-31 2011-02-03 Selexagen Therapeutics Novel hedgehog inhibitors
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
CA2785204C (en) 2010-01-07 2016-01-05 Selexagen Therapeutics, Inc. Hedgehog inhibitors
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CN103108868B (zh) 2010-06-07 2015-11-25 诺沃梅迪科斯有限公司 呋喃基化合物及其用途
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
AU2011293612B2 (en) 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
CN103797006B (zh) 2011-07-13 2016-01-27 诺华股份有限公司 用作端锚聚合酶抑制剂的4-哌啶基化合物
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN102731373B (zh) * 2012-07-19 2013-11-27 南京药石药物研发有限公司 抗肿瘤药物gdc-0449中间体的制备方法
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
EP2895474B1 (en) * 2012-09-17 2019-12-11 Duke University Smoothened receptor modulators and methods of use thereof
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
ES2664782T3 (es) 2012-11-05 2018-04-23 Nantbio, Inc Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
AU2013352256A1 (en) 2012-11-29 2015-06-18 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
CN103910671B (zh) * 2013-01-08 2016-08-10 正大天晴药业集团股份有限公司 Vismodegib及其中间体的制备方法
CN103910672B (zh) * 2013-01-08 2016-10-05 连云港润众制药有限公司 Vismodegib的制备方法
CN103040824B (zh) * 2013-01-17 2015-05-27 四川大学 信号通路抑制剂及其制备方法和用途
WO2014130310A1 (en) 2013-02-19 2014-08-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2976326A4 (en) 2013-03-22 2016-09-21 Shilpa Medicare Ltd PROCESS FOR THE PREPARATION OF SOLID FORMS OF 2-CHLORO-N- (4-CHLORO-3- (PYRIDIN-2-YLPHENYL) -4-METHYLSULFONYLBENZAMIDE
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103254124A (zh) * 2013-04-23 2013-08-21 镇江圣安医药有限公司 N-[4-氯-3–(吡啶-2-基)苯基]-2-氯-4–(甲磺酰基)-苯甲酰胺衍生物及其应用
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
WO2014195977A2 (en) * 2013-06-05 2014-12-11 Hetero Research Foundation Novel polymorphs of vismodegib
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
RU2695815C9 (ru) * 2014-03-24 2019-10-28 Гуандун Чжуншэн Фармасьютикал Ко., Лтд Хинолиновые производные в качестве ингибиторов smo
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015169269A1 (en) 2014-05-05 2015-11-12 Zentiva, K.S. Salts of 2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
EP3177591A1 (en) 2014-08-07 2017-06-14 Basf Se Multi-component crystals of vismodegib and selected co-crystal formers or solvents
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
CN104496889A (zh) * 2014-11-20 2015-04-08 成都平和安康医药科技有限公司 一种工业化合成维莫地尼的方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US9765050B2 (en) 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
MX2017012295A (es) 2015-03-25 2018-01-09 Novartis Ag Derivados formilados n-heterociclicos como inhibidores de fgfr4.
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10464897B2 (en) 2015-06-05 2019-11-05 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EP3310774B1 (en) 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
CN104926714B (zh) * 2015-07-02 2017-07-28 天津大学 2‑氯‑n‑(4‑氯‑3‑(2‑吡啶基)苯基)‑4‑甲基砜苯基苯甲酰胺的制备方法
WO2017050224A1 (zh) * 2015-09-21 2017-03-30 广东众生药业股份有限公司 喹啉衍生物的盐型、晶型及其制备方法和中间体
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
CA3023032A1 (en) 2016-05-04 2017-11-09 Genoscience Pharma Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CN110099900B (zh) * 2016-12-27 2022-12-02 山东大学 针对Smoothened突变株的刺猬通路抑制剂
WO2018133114A1 (en) * 2017-01-23 2018-07-26 Shenzhen University Novel natrural algicide with low toxicity to non-target organisms
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN106892863B (zh) * 2017-03-09 2019-06-11 山东大学 维莫德吉及其中间体的制备方法
GB2560903A (en) * 2017-03-27 2018-10-03 Azad Pharmaceutical Ingredients Ag New synthetic path to pharmaceutically acceptable vismodegib
CN107200708B (zh) * 2017-05-27 2020-03-20 新发药业有限公司 一种维莫德吉的制备方法
CN107556289A (zh) * 2017-06-22 2018-01-09 天津国际生物医药联合研究院 一种氯苯‑吡啶类化合物及其应用
GB201713784D0 (en) * 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) Signalling pathway
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
CA3089566A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of gastrointestinal stromal tumors
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CA3113234A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
AU2019346550A1 (en) 2018-09-25 2021-04-22 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN113164776A (zh) 2018-09-25 2021-07-23 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
EP4282416A3 (en) 2018-09-29 2024-03-06 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
WO2020072540A1 (en) * 2018-10-03 2020-04-09 Nantbio, Inc. A dual inhibitor of wnt/beta-catenin & sonic hedgehog signal transduction pathways
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
US20220040207A1 (en) * 2019-04-02 2022-02-10 The University Of Chicago Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
CN114615982A (zh) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 用于治疗胃肠道间质瘤的瑞普替尼
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CA3150701A1 (en) 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
AU2021409561A1 (en) 2020-12-22 2023-07-06 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
WO2022211811A1 (en) 2021-03-31 2022-10-06 Genentech, Inc. Vismodegib in combination with a replication-deficient type 5 adenovirus for expression of interferon gamma for the treatment of skin cancer
EP4323349A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
EP4323350A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone compounds
TW202317589A (zh) 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物
GB202201283D0 (en) * 2022-02-01 2022-03-16 Omass Therapeutics Ltd Pharmaceutical compounds
WO2023168298A2 (en) * 2022-03-02 2023-09-07 Denali Therapeutics Inc. Compounds, compositions, and methods
US20230303509A1 (en) 2022-03-28 2023-09-28 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023194300A1 (en) 2022-04-05 2023-10-12 Synthon B.V. Solid forms of vismodegib
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024102849A1 (en) 2022-11-11 2024-05-16 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167491A3 (de) * 1984-07-06 1986-12-30 Ciba-Geigy Ag Thiobarbitursäurederivate
JPH0813741B2 (ja) * 1987-08-10 1996-02-14 協和醗酵工業株式会社 抗痴呆剤
JPH02196721A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 抗癌剤
DE4323916A1 (de) * 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
EP0722441A1 (en) * 1993-10-06 1996-07-24 E.I. Du Pont De Nemours & Company Incorporated Herbicidal heteroaryl substituted anilides
DE19500758A1 (de) 1995-01-13 1996-07-18 Basf Ag Substituierte 2-Phenylpyridine
BR9607016A (pt) 1995-02-02 1997-10-28 Smithkline Beecham Plc Derivados de indol como antagonísta de receptor 5-ht
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
ATE286033T1 (de) * 1999-09-16 2005-01-15 Curis Inc Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
FR2801305B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
BR0107384A (pt) * 2000-10-17 2002-09-24 Du Pont Composto, composição para o controle de uma praga invertebrada e método para o controle de uma praga invertebrada
JP4083422B2 (ja) * 2000-12-22 2008-04-30 石原産業株式会社 アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤
CA2432713C (en) * 2000-12-22 2009-10-27 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
EP1394147A4 (en) 2001-06-04 2007-10-24 Eisai R&D Man Co Ltd CARBOXYLENE DERIVATIVE AND A SALT OR AN ESTER CONTAINING MEDICINE
KR20040031782A (ko) 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
EP1427705A2 (en) * 2001-09-21 2004-06-16 E.I. Du Pont De Nemours And Company Insecticidal diamides
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1451160B1 (en) * 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
JPWO2003051876A1 (ja) 2001-12-14 2005-04-28 日本たばこ産業株式会社 ピラゾロピリジン誘導体およびその医薬用途
AU2002367023A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
PL212910B1 (pl) * 2002-02-12 2012-12-31 Smithkline Beecham Corp Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
BR0317525A (pt) * 2002-12-20 2005-11-16 Pharmacia Corp Compostos pirazol acìclico, composição terapêutica e farmacêutica, kit, bem como respectivos usos
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005040152A1 (en) * 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
EP1720855A4 (en) 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
CN102964294A (zh) * 2004-09-02 2013-03-13 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling

Also Published As

Publication number Publication date
NO20071719L (no) 2007-05-31
EA200700538A1 (ru) 2007-10-26
HUS1300068I1 (hu) 2019-03-28
KR101366414B1 (ko) 2014-03-18
KR20070085243A (ko) 2007-08-27
BRPI0514841A (pt) 2008-06-24
US20200010420A1 (en) 2020-01-09
KR20170001725A (ko) 2017-01-04
IL214451A0 (en) 2011-09-27
US9790183B2 (en) 2017-10-17
JP5143558B2 (ja) 2013-02-13
AU2023237067A1 (en) 2023-10-12
US20060063779A1 (en) 2006-03-23
IL181673A (en) 2013-12-31
ATE532768T1 (de) 2011-11-15
EA201100604A1 (ru) 2014-06-30
ES2377430T3 (es) 2012-03-27
US20160152569A1 (en) 2016-06-02
KR20140048343A (ko) 2014-04-23
US20210070707A1 (en) 2021-03-11
AU2005282722B2 (en) 2011-03-03
MX2007002584A (es) 2007-09-07
AU2005282722C1 (en) 2011-08-18
LU92278I9 (xx) 2019-03-06
LU92278I2 (fr) 2013-11-11
EA201890903A1 (ru) 2019-02-28
US9278961B2 (en) 2016-03-08
KR101225018B1 (ko) 2013-01-23
NO339260B1 (no) 2016-11-21
UA96565C2 (ru) 2011-11-25
KR20190072678A (ko) 2019-06-25
KR20160058972A (ko) 2016-05-25
PL1789390T3 (pl) 2012-04-30
KR20150090263A (ko) 2015-08-05
AU2011201229A1 (en) 2011-04-14
EP1789390A2 (en) 2007-05-30
JP2008511675A (ja) 2008-04-17
CY1112630T1 (el) 2015-12-09
CA2579002C (en) 2012-11-27
US20180029984A1 (en) 2018-02-01
PT1789390E (pt) 2012-02-08
CN102964294A (zh) 2013-03-13
CA2579002A1 (en) 2006-03-16
US20110092461A1 (en) 2011-04-21
US7888364B2 (en) 2011-02-15
KR20180122750A (ko) 2018-11-13
SI1789390T1 (sl) 2012-05-31
WO2006028958A3 (en) 2006-04-13
IL181673A0 (en) 2007-07-04
NZ589385A (en) 2011-03-31
CN101072755A (zh) 2007-11-14
US9321761B2 (en) 2016-04-26
EA201890903A9 (ru) 2021-11-10
KR20210090744A (ko) 2021-07-20
KR20200019263A (ko) 2020-02-21
JP2014148537A (ja) 2014-08-21
JP2012184255A (ja) 2012-09-27
KR20120139846A (ko) 2012-12-27
AU2005282722A1 (en) 2006-03-16
KR20130083488A (ko) 2013-07-22
CY2013042I2 (el) 2015-12-09
BRPI0514841B1 (pt) 2021-10-26
WO2006028958A2 (en) 2006-03-16
US20240116872A1 (en) 2024-04-11
CY2013042I1 (el) 2015-12-09
EP1789390B1 (en) 2011-11-09
EA017262B1 (ru) 2012-11-30
DK1789390T3 (da) 2012-02-27
KR20200118909A (ko) 2020-10-16
KR20150002863A (ko) 2015-01-07
US20150105550A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
HUS1300068I1 (hu) A hedgehog jelátvitel piridil inhibitorai
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
EP1713773A4 (en) N-BENZYL-3,4-DIHYDROXYPYRIDINE-2-CARBOXYLIC AMID AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXYLIC AMIDE COMPOUNDS SUITABLE AS INHIBITORS OF THE HIV INTEGRASE
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
WO2007030582A3 (en) Acyclic ikur inhibitors
EP1869060A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS, METHODS OF MAKING INHIBITORS, AND USES THEREOF
MX2009004766A (es) Derivados de espiroindolinona.
GB2432609A (en) Method of expansion
SG155941A1 (en) Inhibitors of the interaction between mdm2 and p53
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
AP2006003549A0 (en) N-substituted benzimidazolyl C-kit inhibitors.
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
TNSN08191A1 (en) Kinase inhibitors
SG150534A1 (en) 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors
TW200732281A (en) Heterocyclic CETP inhibitors
IL180551A0 (en) Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
MY148644A (en) New pharmaceutical compounds
WO2007062314A3 (en) Heterocyclic cetp inhibitors
AP2006003794A0 (en) Combinations of substituted 1-phenyl-1,5-dihydropyrido-Ä3,2-bÜindol-2-ones and other HIV inhibitors
DK1668125T3 (da) Modificerede enzymer, fremgangsmåde til fremstilling af modificerede enzymer og anvendelser deraf
NO20081292L (no) Pentasykliske kinaseinhibitorer
MX2007003398A (es) Sulfonamidas y sus usos.
CA2627497C (en) Heterocyclic amide compound and use thereof